Generic Drugmakers Falter In H108

The first half of 2008 has brought mixed results for pharmaceutical companies operating in Romania. Often considered as a high potential market for investment, it appears that the country's ongoing health reforms may be harming foreign generic makers, particularly those without strong branding for their

To read the full article, please choose one of the following options: